192 related articles for article (PubMed ID: 24160181)
61. Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network.
Nwachukwu JC; Srinivasan S; Bruno NE; Parent AA; Hughes TS; Pollock JA; Gjyshi O; Cavett V; Nowak J; Garcia-Ordonez RD; Houtman R; Griffin PR; Kojetin DJ; Katzenellenbogen JA; Conkright MD; Nettles KW
Elife; 2014 Apr; 3():e02057. PubMed ID: 24771768
[TBL] [Abstract][Full Text] [Related]
62. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Yamamoto Y; Shibata J; Yonekura K; Sato K; Hashimoto A; Aoyagi Y; Wierzba K; Yano S; Asao T; Buzdar AU; Terada T
Clin Cancer Res; 2005 Jan; 11(1):315-22. PubMed ID: 15671561
[TBL] [Abstract][Full Text] [Related]
63. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
[TBL] [Abstract][Full Text] [Related]
64. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites.
Weatherman RV; Clegg NJ; Scanlan TS
Chem Biol; 2001 May; 8(5):427-36. PubMed ID: 11358690
[TBL] [Abstract][Full Text] [Related]
65. The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor alpha in human breast cancer cells.
Maggiolini M; Recchia AG; Bonofiglio D; Catalano S; Vivacqua A; Carpino A; Rago V; Rossi R; Andò S
J Mol Endocrinol; 2005 Oct; 35(2):269-81. PubMed ID: 16216908
[TBL] [Abstract][Full Text] [Related]
66. Insights into ligand selectivity in estrogen receptor isoforms: molecular dynamics simulations and binding free energy calculations.
Zeng J; Li W; Zhao Y; Liu G; Tang Y; Jiang H
J Phys Chem B; 2008 Mar; 112(9):2719-26. PubMed ID: 18266357
[TBL] [Abstract][Full Text] [Related]
67. Estrogen receptor α mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor β.
Galea GL; Meakin LB; Sugiyama T; Zebda N; Sunters A; Taipaleenmaki H; Stein GS; van Wijnen AJ; Lanyon LE; Price JS
J Biol Chem; 2013 Mar; 288(13):9035-48. PubMed ID: 23362266
[TBL] [Abstract][Full Text] [Related]
68. The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.
Vallet A; El Ezzy M; Diennet M; Haidar S; Bouvier M; Mader S
J Biol Chem; 2023 Jan; 299(1):102757. PubMed ID: 36460099
[TBL] [Abstract][Full Text] [Related]
69. Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor α and β subtypes: a molecular modeling study.
Wang P; McInnes C; Zhu BT
PLoS One; 2013; 8(9):e74615. PubMed ID: 24098659
[TBL] [Abstract][Full Text] [Related]
70. Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alpha and beta.
Roelens F; Heldring N; Dhooge W; Bengtsson M; Comhaire F; Gustafsson JA; Treuter E; De Keukeleire D
J Med Chem; 2006 Dec; 49(25):7357-65. PubMed ID: 17149865
[TBL] [Abstract][Full Text] [Related]
71. Structural insights into the mode of action of a pure antiestrogen.
Pike AC; Brzozowski AM; Walton J; Hubbard RE; Thorsell AG; Li YL; Gustafsson JA; Carlquist M
Structure; 2001 Feb; 9(2):145-53. PubMed ID: 11250199
[TBL] [Abstract][Full Text] [Related]
72. Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-alpha expression in the rat uterus.
Reed CA; Berndtson AK; Nephew KP
Anticancer Drugs; 2005 Jun; 16(5):559-67. PubMed ID: 15846122
[TBL] [Abstract][Full Text] [Related]
73. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding.
Zhu BT; Han GZ; Shim JY; Wen Y; Jiang XR
Endocrinology; 2006 Sep; 147(9):4132-50. PubMed ID: 16728493
[TBL] [Abstract][Full Text] [Related]
74. Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism.
Gangloff M; Ruff M; Eiler S; Duclaud S; Wurtz JM; Moras D
J Biol Chem; 2001 May; 276(18):15059-65. PubMed ID: 11278577
[TBL] [Abstract][Full Text] [Related]
75. Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes.
Liu S; Han SJ; Smith CL
Mol Pharmacol; 2013 May; 83(5):1066-77. PubMed ID: 23462505
[TBL] [Abstract][Full Text] [Related]
76. The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene.
Vajdos FF; Hoth LR; Geoghegan KF; Simons SP; LeMotte PK; Danley DE; Ammirati MJ; Pandit J
Protein Sci; 2007 May; 16(5):897-905. PubMed ID: 17456742
[TBL] [Abstract][Full Text] [Related]
77. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
[TBL] [Abstract][Full Text] [Related]
78. Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate.
Tamrazi A; Carlson KE; Daniels JR; Hurth KM; Katzenellenbogen JA
Mol Endocrinol; 2002 Dec; 16(12):2706-19. PubMed ID: 12456792
[TBL] [Abstract][Full Text] [Related]
79. Structural insights into tumor-specific chaperoning activity of gamma synuclein in protecting estrogen receptor alpha 36 and its role in tamoxifen resistance in breast cancer.
Panneerselvam M; Muthu K; Ramadas K
Mol Biosyst; 2015 Nov; 11(11):2998-3010. PubMed ID: 26299756
[TBL] [Abstract][Full Text] [Related]
80. Conformational enantiomerization and estrogen receptor α binding of anti-cancer drug tamoxifen and its derivatives.
Gao L; Tu Y; Wegman P; Wingren S; Eriksson LA
J Chem Inf Model; 2011 Feb; 51(2):306-14. PubMed ID: 21194224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
